Difference between revisions of "LoConte NK, et al. Invest. N. Drugs (2015) cited as Ref 590 in DOI: 10.1038/s41392-020-0110-5 (Q9853)"
Jump to navigation
Jump to search
(Created claim: First Author string (P149): LoConte NK, #quickstatements; #temporary_batch_1589996169159) |
(Created claim: DOI Identifier (P138): 10.1007/s10637-014-0166-6, #quickstatements; #temporary_batch_1590000649558) |
||
| Property / DOI Identifier | |||
| + | |||
| Property / DOI Identifier: 10.1007/s10637-014-0166-6 / rank | |||
| + | Normal rank | ||
Revision as of 19:03, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
LoConte NK, et al. Invest. N. Drugs (2015) cited as Ref 590 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
LoConte NK
0 references
